J7513 – Daclizumab, parenteral, 25 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ7513
- Long description
- Daclizumab, parenteral, 25 mg
- Short description
- Daclizumab, parenteral
- Pricing indicator
51Drugs- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- January 1, 1999
- Last change
- January 1, 2026 – No change
- Termination date
- December 31, 2025
Frequently asked questions
What is HCPCS code J7513?
J7513 is a HCPCS Level II code for daclizumab, parenteral, 25 mg. It was discontinued on December 31, 2025.
Does Medicare cover J7513?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J7505 – Muromonab-cd3, parenteral, 5 mg
- J7506 – Prednisone, oral, per 5 mg
- J7507 – Tacrolimus, immediate release, oral, 1 mg
- J7508 – Tacrolimus, extended release, (astagraf xl), oral, 0.1 mg
- J7509 – Methylprednisolone oral, per 4 mg
- J7510 – Prednisolone oral, per 5 mg
- J7511 – Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg
- J7512 – Prednisone, immediate release or delayed release, oral, 1 mg
- J7514 – Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
- J7515 – Cyclosporine, oral, 25 mg
- J7516 – Injection, cyclosporine, 250 mg
- J7517 – Mycophenolate mofetil, oral, 250 mg
- J7518 – Mycophenolic acid, oral, 180 mg
- J7519 – Injection, mycophenolate mofetil, 10 mg
- J7520 – Sirolimus, oral, 1 mg
- J7521 – Tacrolimus, granules, oral suspension, 0.1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.